Article
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study
Registro en:
LUETKEMEYER, Anne F. et al. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-Based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases, v. 60, n. 12, p. 1860-1863, 2015.
1058-4838
10.1093/cid/civ155
Autor
Luetkemeyer, Anne F.
Rosenkranz, Susan L.
Lu, Darlene
Grinsztejn, Beatriz
Sanchez, Jorge
Ssemmanda, Michael
Sanne, Ian
McIlleron, Helen
Havlir, Diane V.
Haas, David W.
Resumen
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations. 2028-08-30